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Abstract
Aims Myocardial injury during an episode of acute heart
failure (AHF) may be important for patents’ outcome. We
hypothesised that an increase of cardiac troponin levels
(cTnT) during hospitalisation, in patients with undetectable
levels on admission (cTnT release), may be a more specific
marker of myocardial damage. With this aim, we assessed
the clinical and prognostic significance of high serum cTnT
levels at the time of admission and that of cTnT release in
198 consecutive patients admitted for AHF and with no
signs of acute coronary syndrome.
Methods and results cTnT levels were serially measured
at the time of admission, and after 6 and 12 h, in 198
consecutive patients admitted for AHF and with no signs of
acute coronary syndrome. cTnT was detectable ([0.01 ng/
mL) in 102 patients (52 %) and positive for myocardial
necrosis ([0.03 ng/mL) in 78 patients (39 %). Negative
cTnT at the time of admission became positive at 6 and/or
12 h in 36 (18 %) patients. Patients with increased cTnT
levels were more likely to have coronary artery disease,
hypertension, diabetes, and renal dysfunction. During a
median follow-up duration of 247 days (IQR 96–480 days),
the detection of increased cTnT levels was associated with a
higher rate of all-cause deaths and, for cTnT release, all-
cause death and cardiovascular rehospitalisation rate. CTnT
release was an independent predictor of all-cause death and
cardiovascular rehospitalisation, along with glomerular
filtration rate, and the administration of inotropic agents
during the initial hospitalisation.
Conclusions Increased cTnT levels are a frequent finding
in patients with AHF. They are more likely to occur in
patients with comorbidities and are associated with poorer
outcomes. cTnT release is an independent predictor of
poorer outcomes.
Keywords Acute heart failure  Troponin  Prognosis
Introduction
Acute heart failure (AHF) is the most frequent cause of
hospitalisation in patients over 65 years of age [1, 2]. It is
associated with severe symptoms and a poor prognosis,
with an in-hospital mortality ranging from 3 to 7 %, and
mortality rates of 5–15 %, and rehospitalisation rates of
30 % in the 3-6 months after discharge [1–3].
The mechanisms leading to the high event rate in patients
with AHF are still incompletely understood. Acute myo-
cardial damage is one of the most likely mechanisms [2–5].
Increased left ventricular filling pressure and myocardial
stress, hypotension, tachycardia, endothelial dysfunction,
platelet aggregation, activation of neurohormonal and
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inflammatory mechanisms, oxidative stress, and altered
calcium handling may all favour myocytes injury, necrosis
or apoptosis, and/or troponin release even in patients with
angiographically normal coronary arteries [3, 6].
The clinical relevance of these mechanisms is suggested
by studies based on plasma troponins measurements. An
increase of plasma troponin levels has been reported in
30–70 % of patients admitted for AHF, when traditional
methods are used [7–16], and up to 90-100 % of the
patients when high sensitivity assays are used [16, 17].
Such an increase in troponin levels is associated with a
poor prognosis with a dose response relationship between
the magnitude of the increase in circulating troponins and
prognosis [11, 13, 16]. However, these studies are hetero-
geneous with respect of the patients studied, the criteria for
the diagnosis of AHF and the cut-off levels for the defi-
nition of a significant increase in troponin levels.
In addition, previous studies, with only a few exceptions
[10, 12, 16, 17], were based on only a single measurement
taken at the time of admission to the hospital. However, the
myocardial damage detected by an increase in serum tro-
ponin levels at the time of admission may be either pre-
existent, and possibly contributing to the episode of acute
decompensation, or secondary to the AHF itself. [6, 17–19]
This condition may be different from that of an increase in
serum troponin levels occurring during the hospitalisation
in patients with undetectable levels at the time of admis-
sion (troponin release). This second event should be more
specific for an acute myocardial damage secondary to the
episode of acute decompensation. It is, therefore, important
to detect an acute myocardial damage related to the AHF
episode and, with this aim, measurement of serum troponin
concentrations in serially drawn blood samples has been
recently recommended [20].
The aim of this study was to assess the clinical and
prognostic significance of the detection of high serum
cardiac troponin T (cTnT) levels at the time of admission
and that of their increase during hospitalisation, when
undetectable on admission (cTnT release) in consecutive
patients hospitalised for AHF and with no signs of acute
coronary syndrome (ACS). We hypothesised that cTnT
release might have been a more specific marker of myo-
cardial damage related to, if not caused by, the AHF epi-
sode showing a greater prognostic power compared with
increased cTnT at the time of admission.
Methods
Patients
This was a prospective, observational study in patients
admitted with a diagnosis of AHF at the Institute of
Cardiology of the University of Brescia. AHF was
diagnosed on the basis of the criteria of the European
Society of Cardiology as a rapid onset or change in the
signs and symptoms of HF, resulting in the need for
urgent therapy [1]. Treatment with C40 mg of furose-
mide administered intravenously was required as an
inclusion criterion. Patients with ACS, myocarditis, car-
diac tamponade, aortic dissection or evidence of non-
cardiovascular factors as the main cause of symptoms
were excluded. According to the universal definition of
acute myocardial infarction, the diagnosis of ACS was
made on the basis of concomitant typical symptoms and
ECG changes indicative of myocardial ischaemia (new
ST-T changes or new LBBB) and/or development of
pathological Q-waves and/or imaging evidence of a new
regional wall motion abnormality [21]. These patients
were excluded from our study.
All patients underwent complete clinical examination at
the time of hospital admission, and, on at least a daily
basis, thereafter, until the time of hospital discharge. Blood
samples were obtained at the time of hospital admission,
before the start of intravenous therapy, and at 6 and 12 h
after admission. Doppler-echocardiography was performed
within 12 h after the initiation of intravenous therapy. The
diagnosis of ischaemic aetiology of HF was based on a
history of myocardial infarction and/or documented coro-
nary artery disease or, when absent but an ischaemic cause
suspected, on the results of a coronary angiography per-
formed during the hospitalisation. Decisions about hospital
discharge were made based on clinical evaluation, and
treating physicians were blinded to cTnT values which
were measured after patient’s discharge by an independent
laboratory.
Patient’s follow-up was performed through visits at
our outpatients unit or, when not possible, through
telephone calls with the patient or her/his physician
and/or relatives. The study was approved by our hospi-
tal’s Ethics Committee. All patients signed a written
informed consent form regarding their enrolment into
this study.
Troponin assay
Venous blood samples were collected in tubes without
anticoagulant (S-Monovette, Sarstedt), centrifuged at
3,000 rpm for 15 min and serum was immediately stored at
-20C until analysis. Cardiac troponin T was measured on
an Elecsys 2010 analyzer (Roche Diagnostics GmbH),
using a third generation assay (Troponin T STAT, Roche
Diagnostics). The detection limit of the assay is 0.01 ng/
mL and the decision limit used for myocardial necrosis is
0.03 ng/mL. Glomerular filtration rate was calculated by
the MDRD equation [22].
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Patients classification
The measurement of abnormal cTnT values was entered as
a categorical variable with patients classified on the basis
of their cTnT levels. Each patient was classified in three
different categories based on the presence of detectable or
undetectable serum cTnT levels, positive or negative cTnT
levels for myocardial necrosis, and, finally, on the finding
of a cTnT release or not, during the hospitalisation. The
first classification was performed using the limit of detec-
tion of the analytical method as cut-off: cTnT [0.01 ng/
mL (detectable) versus cTnT B0.01 ng/mL (undetectable).
The second classification was performed using cTnT levels
defined as positive for myocardial necrosis: cTnT
[0.03 ng/mL (positive) versus cTnT B0.03 ng/mL (nega-
tive). The cut-off value of 0.03 ng/mL was chosen as
greater than the 10 % coefficient of variation of this mea-
surement. Finally, cTnT release was defined by the detec-
tion of at least one positive value ([0.03 ng/mL) during
hospitalisation associated with negative cTnT levels at
baseline [23]. These patients were compared to those with
no cTnT release, regardless of the presence of high levels
at admission.
Statistical analysis
All data are shown as mean ± standard deviation unless
otherwise specified. Median and interquartile range (IQR)
values are shown when data did not have a normal distri-
bution with differences between the mean and the median
values. Continuous variables are compared by T test. Cat-
egorical variables are presented as percentages and com-
pared by Chi-square test or Fisher exact test.
Cumulative survival estimates were calculated using the
Kaplan–Meier method. Survival differences related to the
main risk factors were evaluated by the long-rank method
and the relative prognostic value of cTnT was calculated by
the Cox univariate analysis. To assess the independent
prognostic value of increased cTnT levels, this variable
was entered into a multivariable model including variables
traditionally related with outcomes in AHF [24–26]. A
P value \0.05 was considered significant.
The primary endpoint of the study was all-cause death or
cardiovascular (CV) hospitalisations. As in-hospital deaths
could have influenced the prognostic value of variables
measured during hospitalisation, namely cTnT release, we
included into our study only the 198 patients who were
discharged alive from hospital and excluded 5 patients who
died during the hospitalisation.
The size of the study group was calculated with the
primary aim of assessing the power of the measurement of
serum cTnT levels to predict the incidence of major car-
diovascular events (all-cause death or CV hospitalisation).
Assuming an incidence of death or CV hospitalisation of
50 % we calculated that a sample size of 196 patients
discharged alive from hospital would have allowed an
80 % power, with an alpha value of 0.05, to detect a hazard
ratio (HR) of 0.56 with respect of the risk of events in the
patients with increased serum cTnT levels versus the
others.
Results
We enrolled 198 consecutive patients admitted for AHF
between January 2007 and December 2008 and discharged
alive from hospital. No patient was lost during follow-up.
During a mean follow-up of 297 ± 233 days (median
247 days, IQR 96–480 days), 49 patients (25 %) died and
111 (56 %) died or were hospitalised for cardiovascular
reasons. Four patients (2 %) underwent heart transplant.
Detectable and positive cTnT levels on admission
The demographic characteristics of the patients and their
clinical and laboratory values at the time of admission
according to cTnT levels are summarised in Table 1. The
mean age was 68 ± 12 years, 116 patients (58 %) had an
ischaemic cardiomyopathy, 68 (34 %) had no coronary
artery disease (idiopathic dilated cardiomyopathy or
hypertensive heart disease), and 14 patients had a primary
valve disease as a cause of AHF.
Serum cTnT was detectable ([0.01 ng/mL) in 102
patients (52 %) and positive for myocardial necrosis
([0.03 ng/mL) in 78 patients (39 %). An ischaemic aeti-
ology of HF was present in 68 patients (67 %) of those
with detectable cTnT and in 56 (72 %) of those with
positive cTnT levels.
Compared with the others, patients with detectable cTnT
were older, had a higher prevalence of diabetes, ischaemic
heart disease (67 vs. 50 %), and a higher heart rate, serum
glucose, blood urea nitrogen (BUN) and creatinine levels, a
lower estimated glomerular filtration rate (eGFR) and
received higher doses of i.v. furosemide and were more
likely to be treated with i.v. vasodilators during the hos-
pitalisation (Table 1).
Similar to what found for patients with detectable cTnT
levels, patients with cTnT positive for myocardial necrosis
(cTnT [0.03 ng/mL) were older, had a higher prevalence
of ischaemic heart disease (72 vs. 50 %), hypertension and
diabetes, a higher heart rate, serum glucose, BUN and
creatinine levels, a lower eGFR and received higher doses
of i.v. furosemide and were more likely to be treated with
i.v. vasodilators during the hospitalisation.
Both detectable and positive cTnT levels were associ-
ated with a higher mortality rate. Among those with
Clin Res Cardiol
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detectable cTnT levels there were 32 deaths (31 %),
compared to 17 deaths (18 %) in those without detectable
troponin. Similarly, among those with evidence of myo-
cardial necrosis, there were 27 deaths (35 %) compared to
22 deaths (18 %) amongst those without myocardial
necrosis. Similar trends were found for the combined
endpoint of all-cause death or cardiovascular hospitalisa-
tion. For detectable cTnT the combined end-point occurred
in 63 patients (62 %) with detectable cTnT versus 48
patients (50 %) without detectable troponin. The combined
endpoint occurred in 50 patients (64 %) with myocardial
necrosis, versus 61 patients (51 %) without myocardial
necrosis. Death and hospitalisation rates according to cTnT
levels are outlined in Table 2. Cumulative 1-year cardio-
vascular hospitalisation-free survival curves are shown in
Figs. 1 and 2.
Troponin release
Thirty-six (18 %) of the studied patients had a cTnT
release during hospitalisation. Twenty-six of them (72 %)
had concomitant coronary artery disease. When compared
to the others, patients with cTnT release were older, had
higher prevalence of diabetes and renal dysfunction, higher
serum BUN and creatinine levels and lower GFR. They
also had higher heart rate and received higher doses of i.v.
furosemide and were more likely to be treated with i.v.
vasodilators during the hospitalisation (Table 1).
Death for any cause occurred in 13 patients with cTnT
release (36 %) compared to 36 (22 %) in those without,
while the combined end-point of all-cause death or car-
diovascular hospitalisation occurred in 27 (75 %) versus
84 (52 %) patients (P = 0.011) (Table 1). Cumulative
1-year hospitalisation-free survival rate was 10 %
amongst the patients with cTnT release, versus 42 % in
the others (P \ 0.001) (Fig. 3). Among the 36 patients
with cTnT release, 10 had their peak value at 6 h with a
decrease at the 12-h measurement. No difference was
found between this last subgroup of patients and the others
with cTnT release with respect of any clinical variable and
outcomes.
Multivariable analysis
Both detectable and positive cTnT levels and cTnT release
were entered into a multivariable Cox regression model
including all the variables significant at univariable anal-
ysis. The variables selected as predictive for all-cause
death or cardiovascular hospitalisation were cTnT release,
treatment with inotropic agents, and eGFR (Table 3).
Kaplan–Meier survival curves for patients subdivided on
the basis of cTnT release and treatment with inotropic
agents are shown in Fig. 4. T
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Discussion
Our study shows that a high proportion of patients admitted
for AHF has an increase in cTnT levels with 52 % of our
patients with detectable cTnT levels, 39 % of the patients
with levels positive for acute myocardial infarction and
18 % of the patients with levels initially negative who then
become positive for myocardial necrosis during the hos-
pitalisation (cTnT release). Patients with increased cTnT
levels had a higher heart rate, were more likely to have an
ischaemic aetiology of AHF, had greater comorbidities
(hypertension, diabetes, and renal dysfunction), and were
more likely to receive i.v. vasodilators during the hospi-
talisation. Patients with increased cTnT levels had higher
rates of mortality and with respect to cTnT release
Fig. 1 Kaplan–Meier cardiovascular hospitalisation-free survival
curves of the patients with detectable and undetectable cTnT levels
at the time of admission to hospital
Fig. 2 Kaplan–Meier cardiovascular hospitalisation-free survival
curves of the patients with cTnT levels positive or negative for
myocardial necrosis at the time of admission to hospital
Fig. 3 Kaplan–Meier cardiovascular hospitalisation-free survival
curves of the patients subdivided on the basis of cTnT release
Fig. 4 Kaplan–Meier cardiovascular hospitalisation-free survival
curves of the patients subdivided on the basis of cTnT release
administration of i.v. inotropes during the initial hospitalisation
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remained a significant predictor for the primary endpoint
also at multivariable analysis, along with a low GFR and
treatment with inotropic agents.
Our results confirm and extend previous findings that a
high proportion of patients with AHF have increased cTnT
levels. Our finding of detectable cTnT levels in 52 % of
our patients is very close to the prevalence of 49 %,
described by Biolo et al. [15] in 39 patients with AHF, as
well as to the prevalence of detectable TnI of 73.9 % and
TnT 43.5 % shown by Gheorghiade et al. [10]. Lower
percentages (6.2–49 %) were shown by studies based on
only one measurement taken at the time of admission for
AHF [11, 13], and in studies in patients with chronic stable
HF [7, 27, 28].
Studies using high sensitivity troponin assays have
found detectable levels in a higher proportion of patients
with heart failure, often close to 100 % of the patients
studied [16, 17, 29]. These results are consistent with those
obtained in other conditions not associated with coronary
artery disease, such as supraventricular tachyarrhythmias,
acute pulmonary embolism, sepsis, stroke, and strenuous
exercise [30–33]. The magnitude of the increase in tropo-
nin levels is generally less and persists for a shorter period
of time compared with the troponin increases associated
with acute myocardial infarction. In this setting, the ele-
vation in high sensitivity troponin levels has been generally
associated with poorer outcomes with a continuous relation
between the magnitude of the troponin increase and the
likelihood of poorer outcomes. However, despite its clini-
cal significance, the relation between the increase in high
sensitivity troponin levels and reversible or irreversible
myocardial injury is still unsettled [30]. Recently,
increased serum levels of cTnT have been shown in
patients with diseased skeletal muscle in the absence of
cardiovascular disease and their source from the diseased
skeletal muscle has been shown [34, 35]. This may be a
further reason for a stable increase in cTnT levels in
patients with heart failure as a skeletal muscle disease may
coexist in this condition [36].
Few studies have examined the prognostic significance
of serial measurements of cTnT levels. These were mainly
done in ambulatory patients with chronic HF and have
shown that patients who develop detectable cTnT levels
[37] and who have multiple elevations of cTnT [38] have a
higher risk of death or transplantation. In another study,
serum TnI and BNP levels were measured on admission,
discharge, and up to four consecutive days during hospi-
talisation in 140 patients with AHF. Increased TnI and
BNP were each associated with an increased risk of death
or rehospitalisation. Patients with increasing TnI during
hospitalisation had increased mortality compared with
patients with stable or decreasing TnI [16].
In our study, we have evaluated, the clinical significance
of the occurrence of increased cTnT levels during a hos-
pitalisation for acute HF (cTnT release), compared with the
detection of high serum levels at the time of admission.
This finding is potentially important as the detection of
increased cTnT at the time of admission may be an index
of an ongoing myocardial damage, likely related to
mechanisms occurring before the hospitalisation and pos-
sibly favouring the acute decompensation. In contrast, the
occurrence of cTnT release during the hospitalisation
should be ascribed to mechanisms related to the episode of
acute decompensation, such as the hemodynamic changes
and the treatment administered for acute HF [6]. A cTnT
release occurred in 18 % of our patients. Similar to the
patients with detectable cTnT levels at the time of admis-
sion, also these patients had an increased risk of death
or re-hospitalisation. However, interestingly, only cTnT
release, but not the detection of increased cTnT at baseline,
Table 3 Results of Cox
univariable and multivariable
analysis for primary endpoint
all-cause death or CV
hospitalisations
a Only the variables significant
at multivariable analysis are
shown
Univariable analysis Multivariable analysisa
HR 95 % CI P value HR 95 % CI P value
TnT [0.01 lg/L 1.513 1.006–2.28 0.047
TnT [0.03 lg/L 1.477 0.986–2.21 0.059
TnT release 1.83 1.202–2.797 0.003 1.786 1.151–2.771 0.010
Diabetes 1.59 1.089–2.312 0.017
I.v. nitrates 1.21 0.786–1.858 0.381
I.v. inotropic agents 2.31 1.541–3.464 \0.001 2.279 1.495–3.475 \0.001
Age [70 years 1.11 0.764–1.623 0.575
Glucose [110 mg/dL 1.38 0.866–2.187 0.164
Bilirubin (median) 0.76 0.496–1.164 0.201
Heart rate (median) 1.28 0.877–1.855 0.203
eGFR bs 0.986 0.979–0.993 \0.001 0.991 0.983–0.998 0.014
Creatinine [1.3 mg/dL 2.15 1.447–3.208 \0.001
Ischaemic aetiology 1.65 1.108–2.446 0.015
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was selected as an independent variable related with out-
comes by our multivariable analysis. This finding indicates
the value of serial cTnT measurements during an episode
of acute HF and this is consistent with recent statements
[20] and recent results [23].
Our study shows that patients with increased cTnT
levels have a high prevalence of coronary artery disease,
diabetes, hypertension, renal dysfunction. All these
comorbidities are associated with an increased likelihood
of myocardial injury. Renal dysfunction may also increase
the likelihood of the detection of increased cTnT levels.
However, both cTnT release and low eGFR were related
with outcomes at multivariable analysis, thus showing their
independent role.
The higher heart rate of patients with increased cTnT
levels is consistent with the role of tachycardia as a cause
of myocardial ischaemia also in the setting of AHF. It is
possible that concomitant beta-blocker therapy and/or the
use of other bradycardic agents may reduce the incidence
of myocardial ischaemia and maybe improve patients’
prognosis [39].
The role of concomitant treatment is also noteworthy.
Patients with increased cTnT levels received higher doses
of furosemide during the first day of hospitalisation. This is
consistent with the higher prevalence of renal dysfunction
and the greater severity of AHF in these patients. Our
patients with increased cTnT were also more likely to be
treated with i.v. vasodilators, but not with i.v. inotropes.
Also in this case, concomitant treatment seems more a
consequence of comorbidities found in our patients, rather
than a cause of cTnT release. As coronary artery disease
and hypertension were more frequent in our patients with
increased cTnT levels, they were also more likely to be
treated with vasodilators and less likely to receive ino-
tropes which are known to be associated with a worse
prognosis in ischaemic patients [40]. However, our data do
not exclude the hypothesis that the drop of blood pressure
associated with excessive vasodilator therapy may have
favoured myocardial ischaemia in some patients. Untoward
effects of vasodilators have been shown also in previous
studies [41].
The strong association of increased cTnT levels with
poorer outcomes suggest that myocardial damage, as well
as renal dysfunction and administration of inotropic agents,
may be a mechanism which favours the progression of
cardiac dysfunction and causes the poor prognosis of the
patients with AHF. However, our data do not allow
excluding that cTnT, as well as other variables related with
prognosis, is just an epiphenomenon of more severe AHF.
One limitation of our study is the lack of measurement
of natriuretic peptides (NPs) plasma levels. B-type NP and
Nt-proBNP are markers of myocytes strain and increased
intracardiac pressures and are well established tools for the
diagnosis of heart failure and the prognostic assessment of
these patients. High NPs levels at the time of hospitalisa-
tion for acute heart failure are independent predictors of in-
hospital mortality, [42]; length of in-hospital stay [41]; and
post-discharge mortality [43]. Serial assessment of NPs
levels provides further information with respect of prog-
nosis [44], and levels measured at the time of discharge are
independent predictors of poor prognosis [45, 46]. Cardiac
troponins have been investigated in combination with NPs
in the setting of acute heart failure. Earlier studies with
second and third generation assays for cTn showed that
both biomarkers are independently related with future
cardiac events [47], with an additive prognostic value [12,
48, 49]. Similar conclusions were reached also in studies
evaluating NP and hsTn [16, 50, 51]. This is consistent
with the fact that Tn and NPs are related to different
pathophysiological mechanisms: myocardial stretch and
myocardial damage, respectively. Evaluation of cTn
plasma levels may therefore provide useful, supplemental
information independently from NPs.
Another limitation of our study is the relatively small
number of patients. However, our study group is larger
than in most of the previous studies and, differently from
most of the previous studies, serum cTnT levels were
measured serially at baseline, 6 and 12 h after hospitali-
sation, rather than only at the time of admission. It is likely
that the study of a larger study group may have allowed a
better assessment of variables related with outcomes.
Because of the relatively low number of events, we have
limited our multivariable analysis to only the combined
end-point of death or cardiovascular hospitalisation, with-
out assessing mortality alone.
In conclusion, our study confirms previous findings with
respect of the high prevalence of increased cTnT levels in
patients admitted for AHF. In addition, it shows that a
significant proportion (18 %) of patients may develop
cTnT release during hospitalisation. Either detectable or
positive cTnT levels or cTnT release were associated with
a poor prognosis but only cTnT release remained signifi-
cant after adjustment for baseline variables.
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